The report evaluates the analytical validity, clinical validity, and clinical utility of the FirstSightCRC test, a liquid biopsy test that detects and analyzes circulating tumor cells (CTCs) and is intended to predict the likelihood of having precancerous adenomatous polyps or colorectal cancer (CRC) in patients eligible for CRC screening.

If you have a Hayes login, click here to view the full report on the Knowledge Center.